MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

MEI Pharma (MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

November 30, 2021 7:18 AM EST

MEI Pharma (NASDAQ: MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

... More